S. Muoio & CO. LLC purchased a new stake in Spark Therapeutics Inc (NASDAQ:ONCE) during the first quarter, according to its most recent filing with the SEC. The fund purchased 50,000 shares of the biotechnology company’s stock, valued at approximately $5,694,000. Spark Therapeutics comprises about 5.2% of S. Muoio & CO. LLC’s portfolio, making the stock its 4th largest holding.
Several other institutional investors have also bought and sold shares of the company. State Board of Administration of Florida Retirement System increased its holdings in shares of Spark Therapeutics by 1.2% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 17,916 shares of the biotechnology company’s stock worth $2,040,000 after buying an additional 220 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Spark Therapeutics by 7.0% during the 4th quarter. SG Americas Securities LLC now owns 4,806 shares of the biotechnology company’s stock worth $188,000 after purchasing an additional 313 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in shares of Spark Therapeutics by 10.7% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 4,117 shares of the biotechnology company’s stock worth $469,000 after purchasing an additional 399 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Spark Therapeutics by 16.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,460 shares of the biotechnology company’s stock worth $135,000 after purchasing an additional 485 shares during the period. Finally, Sterling Investment Advisors Ltd. purchased a new position in shares of Spark Therapeutics during the 1st quarter worth about $68,000.
ONCE has been the subject of a number of recent analyst reports. Zacks Investment Research cut shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $80.00 price target (down from $103.00) on shares of Spark Therapeutics in a research note on Thursday, January 10th. Credit Suisse Group reaffirmed a “hold” rating and set a $44.00 price target on shares of Spark Therapeutics in a research note on Friday, February 8th. William Blair reaffirmed a “buy” rating on shares of Spark Therapeutics in a research note on Tuesday, February 19th. Finally, Mizuho cut shares of Spark Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, February 25th. Eighteen investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Spark Therapeutics presently has an average rating of “Hold” and an average price target of $78.45.
Spark Therapeutics stock traded down $0.12 during trading hours on Thursday, hitting $109.39. The company had a trading volume of 15,619 shares, compared to its average volume of 1,566,004. The stock has a market cap of $4.18 billion, a price-to-earnings ratio of -51.91 and a beta of 2.48. The company has a debt-to-equity ratio of 0.09, a current ratio of 9.10 and a quick ratio of 8.68. Spark Therapeutics Inc has a 1 year low of $34.53 and a 1 year high of $114.20.
Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Tuesday, February 19th. The biotechnology company reported ($1.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.89). Spark Therapeutics had a negative net margin of 121.78% and a negative return on equity of 14.94%. The company had revenue of $13.15 million during the quarter, compared to analysts’ expectations of $26.76 million. During the same period last year, the firm earned ($1.63) earnings per share. Spark Therapeutics’s quarterly revenue was up 47.9% on a year-over-year basis. Research analysts expect that Spark Therapeutics Inc will post -4.52 earnings per share for the current year.
About Spark Therapeutics
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.
Read More: Purposes and Functions of the Federal Reserve
Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).